<DOC>
	<DOCNO>NCT00936442</DOCNO>
	<brief_summary>ARTEMIS study assess educational material affect overall adherence anastrozole evaluation patient ' electronically compile dosing history . Patients ' dose time compile electronically use Medication Event Monitoring System '' ( MEMS® ) order able gather accurate , objective up-to-date patient ' dose history . For subject Group A , control group , adherence anastrozole standard clinical practice evaluate . For subject Group B , top standard clinical practice , also receive educational material mail week 0 ( study registration ) , week 2 , week 4 , week 6 , week 8 , week 12 , month 5 , month 7 , month 10 . This procedure ongoing CARIATIDE study . One reason poor adherence ( either early discontinuation treatment miss dos still engage therapy ) side effect experience patient anastrozole treatment . Recording reason discontinuation allow u identify reason treatment discontinuation . Recording reason anastrozole interruption study period allow u relate event patient ' adherence anastrozole . During study , pro-active safety data collection take place . Spontaneous report adverse drug reaction ( ADRs ) report accord local post-marketing pharmacovigilance regulation .</brief_summary>
	<brief_title>Arimidex Therapy Compliance Electronic Monitoring System</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<criteria>Postmenopausal woman hormone sensitive early breast cancer . Documented decision treatment anastrozole start 13 week accord current SmPC OR current treatment anastrozole accord current SmPC , exceed thirteen week enrollment . Subjects accept use MEMS® monitor automatically compile drug dose history . Concomitant previous use adjuvant tamoxifen , letrozole exemestane current tumour . Involvement plan and/or conduct study ( applies AstraZeneca staff staff study site ) . Participation another clinical study investigational product last 3 month .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Compliance</keyword>
	<keyword>Early Breast Cancer</keyword>
</DOC>